# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-096895
Filing Date
2025-04-25
Accepted
2025-04-25 16:18:47
Documents
16
Period of Report
2025-06-05

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d923242ddef14a.htm iXBRL | DEF 14A | 627571
3 | GRAPHIC | g923242dsp010.jpg | GRAPHIC | 159399
4 | GRAPHIC | g923242dsp011.jpg | GRAPHIC | 120131
5 | GRAPHIC | g923242g40g40.jpg | GRAPHIC | 93547
6 | GRAPHIC | g923242g51i53.jpg | GRAPHIC | 120550
| Complete submission text file | 0001193125-25-096895.txt |  | 2446542

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA | svra-20241231.xsd | EX-101.SCH | 2506
18 | EXTRACTED XBRL INSTANCE DOCUMENT | d923242ddef14a_htm.xml | XML | 173494

Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32157 | Film No.: 25874364
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)